VISCHER’s advised Genedata on the deal. Genedata AG, a leading provider of software solutions for biopharmaceutical R&D, has been acquired by Danaher Corporation (NYSE: DHR), a...
Danaher Corporation’s Acquisition Of Genedata AG
EnBW’s Partnership With Narrowin GmbH
VISCHER advised narrowin GmbH on all aspects on this transaction. The German energy supplier EnBW enters into a partnership with narrowin GmbH, a Swiss cybersecurity start-up....
LimmaTech Biologics AG’s $37 Million Series A Financing Round
VISCHER acted as legal advisor to LimmaTech Biologics in the transaction. LimmaTech Biologics AG closed a USD 37m (CHF 33m) Series A financing round co-led by Adjuvant...
Innov Ad N.V.’s Acquisition of Herbonis AG
VISCHER advised the selling Herbonis shareholders in this transaction. Innovad, a leading provider of animal nutrition and health solutions, is pleased to announce that it is...
European Biotech Acquisition’s $200 Million Combination With Oculis
Davis Polk advised European Biotech Acquisition Corp. on the deal while Cooley and Vischer represented Oculis. European Biotech Acquisition Corp. (EBAC), a SPAC, signed its $200 million...
Forty51 Ventures’ $43 Million Fundraising
VISCHER and Dechert advised Forty51 Ventures on the deal. FORTY51 Ventures, a Biotech venture capital firm, closed its first fund, FORTY51 Ventures Fund I SCSp, FIAR,...
Sunrise’s Acquisition of EBL’s Telecom Division
VISCHER advised EBL on the deal. Swiss full-service provider Sunrise has signed an agreement to acquire the telecom business of utility firm EBL. EBL has been...
Novaremed’s Option and License Agreement With NeuroFront
VISCHER advised Novaremed AG on the deal. Novaremed AG, a privately held clinical-stage biopharmaceutical company and NeuroFront Therapeutics (Hong Kong) Limited, a China-based clinical stage neuroscience...
ImmunOs Therapeutics’ CHF 71 Million Series B Financing Round
Lenz & Staehelin advised co-lead investors Samsara Biocapital and Lightspeed Venture Partners as their Swiss counsel. VISCHER advised ImmunOs. Walder Wyss advises Gimv. ImmunOs Therapeutics AG,...
Anaveon’s CHF 110 Million Series B Financing Round
VISCHER advised Anaveon on the deal. Anaveon AG, a Swiss clinical-stage immuno-oncology company, has agreed to a CHF 110m Series B financing led by incoming investor...
Msg Systems AG’s Acquisition of Optravis LLC
VISCHER advised Optravis on the deal. msg systems ag, an international IT consulting and system integration company based in Munich, has acquired Optravis LLC, based in...
Novaremed’s Acquisition of Metys Pharmaceuticals
VISCHER AG advised Novaremed on the deal. Novaremed, a privately held clinical-stage biopharmaceutical company, expands its pipeline of non-opioid treatment candidates for chronic pain indications through...